Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as a treatment for obstructive sleep apnoea (OSA) after hitting the mark in a pair of phase 3 trials.
Amgen is lagging behind rivals like Novo Nordisk and Eli Lilly with its new-generation therapy for obesity, but is sufficiently encouraged by early-stage clinical data to kick off a phase 2
Eli Lilly has decided to wait for the readout of the second of its two phase 3 trials for tirzepatide in obesity, rather than filing on the strength of its first, positive study.
Denmark's Novo Nordisk has been almost single-handedly rebuilding the market for drugs to treat obesity over the last few years with its GLP-1 agonist drugs
Novo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which it believes has the potential to redefine the market for weight-loss medicine
Eli Lilly has scored five out of five with its phase 3 trials of type 2 diabetes candidate tirzepatide, setting up regulatory filings for a drug that the drugmaker thinks could be the lynch
Digital investment in the pharma sector is continuing at a steady pace but could fall behind what is needed to deliver true transformation of their businesses.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.